The National Review of Asthma Deaths (NRAD) came out a decade ago, yet as a nation, we still have the highest asthma death rate in Europe - four times that of Italy or the Netherlands. This is unsurprising, considering many patients still rely on their blue inhalers alone.

On the 28th November the joint National Institute for Health and Care Excellence (NICE), British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN) will publish their long-awaited single guideline on asthma diagnosis, monitoring and management.

This is a high-level summary of what the new BTS/NICE/SIGN Asthma: diagnosis monitoring and chronic asthma management guideline means for you as a primary healthcare professional and what steps you need to take to implement it effectively. 

It is not a tick box template – all consultations with patients should be approached holistically and tailored specifically to the patient’s needs, requirements and other co-morbidities and situations.

We have issued pragmatic guidance for the routine and crisis management of patients with asthma and COPD during the UK Covid-19 epidemic.

Asthma Guidelines in Practice – A PCRS Consensus is a practical and pragmatic guide for healthcare professionals working in primary and intermediate care.  This guide was commissioned to provide clarity on aspects of diagnosis, management and monitoring of asthma that are uncertain

Are you struggling to persuade your Integrated Care Board (ICB) to fund FeNO testing? With the new BTS/NICE/SIGN asthma guideline recommending FeNO for asthma diagnostic testing, this can create quite a challenging for primary care providers.

The Medicines and Healthcare products Regulatory Agency (MHRA) has put out a reminder for healthcare professionals and patients with asthma that overuse of blue inhalers (short-acting beta 2 agonists or SABAs), without use of a preventer inhaler, may lead to worsening symptoms or serious asthma a